FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094129893> ?p ?o ?g. }

• W2094129893 abstract "Haemodialysis (HD) is critically dependent on the availability of adequate access to the systemic circulation, ideally via a native arteriovenous fistula (AVF). The Primary failure rate of an AVF ranges between 20-54%, due to thrombosis or failure of maturation. There remains limited evidence for the use of anti-platelet agents and uncertainty as to choice of agent(s) for the prevention of AVF thrombosis. We present the study protocol for a randomised, double-blind, placebo-controlled, clinical trial examining whether the use of the anti-platelet agents, aspirin and omega-3 fatty acids, either alone or in combination, will effectively reduce the risk of early thrombosis in de novo AVF.The study population is adult patients with stage IV or V chronic kidney disease (CKD) currently on HD or where HD is planned to start within 6 months in whom a planned upper or lower arm AVF is to be the primary HD access. Using a factorial-design trial, patients will be randomised to aspirin or matching placebo, and also to omega-3 fatty acids or matching placebo, resulting in four treatment groups (aspirin placebo/omega-3 fatty acid placebo, aspirin/omega-3 fatty acid placebo, aspirin placebo/omega-3 fatty acid, aspirin/omega-3 fatty acid). Randomisation will be achieved using a dynamic balancing method over the two stratification factors of study site and upper versus lower arm AVF. The medication will be commenced pre-operatively and continued for 3 months post surgery. The primary outcome is patency of the AVF at three months after randomisation. Secondary outcome measures will include functional patency at six and twelve months, primary patency time, secondary (assisted) patency time, and adverse events, particularly bleeding.This multicentre Australian and New Zealand study has been designed to determine whether the outcome of surgery to create de novo AVF can be improved by the use of aspirin and/or omega-3 fatty acids. Recently a placebo-controlled trial has shown that clopidogrel is effective in safely preventing primary AVF thrombosis, but ineffective at increasing functional patency. Our study presents significant differences in the anti-platelet agents used, the study design, and surgical and patient demographics that should contribute further evidence regarding the efficacy of anti-platelet agents.Australia & New Zealand Clinical Trials Register (ACTRN12607000569404)." @default.
• W2094129893 created "2016-06-24" @default.
• W2094129893 creator A5012365523 @default.
• W2094129893 creator A5015471784 @default.
• W2094129893 creator A5018662602 @default.
• W2094129893 creator A5019279914 @default.
• W2094129893 creator A5024768204 @default.
• W2094129893 creator A5025675098 @default.
• W2094129893 creator A5045012584 @default.
• W2094129893 creator A5054774219 @default.
• W2094129893 creator A5055253820 @default.
• W2094129893 creator A5062613865 @default.
• W2094129893 creator A5085708536 @default.
• W2094129893 creator A5087336965 @default.
• W2094129893 creator A5090037493 @default.
• W2094129893 date "2009-01-21" @default.
• W2094129893 modified "2023-10-16" @default.
• W2094129893 title "Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study" @default.
• W2094129893 cites W1502557493 @default.
• W2094129893 cites W1851119210 @default.
• W2094129893 cites W1928878693 @default.
• W2094129893 cites W1967514197 @default.
• W2094129893 cites W1980635794 @default.
• W2094129893 cites W1984450372 @default.
• W2094129893 cites W1986862277 @default.
• W2094129893 cites W1987014609 @default.
• W2094129893 cites W2007080140 @default.
• W2094129893 cites W2013800720 @default.
• W2094129893 cites W2016843596 @default.
• W2094129893 cites W2018671066 @default.
• W2094129893 cites W2022343137 @default.
• W2094129893 cites W2041077498 @default.
• W2094129893 cites W2044740389 @default.
• W2094129893 cites W2052620776 @default.
• W2094129893 cites W2057897080 @default.
• W2094129893 cites W2073772081 @default.
• W2094129893 cites W2076791931 @default.
• W2094129893 cites W2086794860 @default.
• W2094129893 cites W2092167363 @default.
• W2094129893 cites W2108659066 @default.
• W2094129893 cites W2114028495 @default.
• W2094129893 cites W2114249119 @default.
• W2094129893 cites W2116421100 @default.
• W2094129893 cites W2116701785 @default.
• W2094129893 cites W2118528604 @default.
• W2094129893 cites W2125214696 @default.
• W2094129893 cites W2129663436 @default.
• W2094129893 cites W2135559852 @default.
• W2094129893 cites W2138678834 @default.
• W2094129893 cites W2149011476 @default.
• W2094129893 cites W2156923368 @default.
• W2094129893 cites W2157949927 @default.
• W2094129893 cites W2169089638 @default.
• W2094129893 cites W2062449634 @default.
• W2094129893 doi "https://doi.org/10.1186/1471-2369-10-1" @default.
• W2094129893 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2637871" @default.
• W2094129893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19159453" @default.
• W2094129893 hasPublicationYear "2009" @default.
• W2094129893 type Work @default.
• W2094129893 sameAs 2094129893 @default.
• W2094129893 citedByCount "45" @default.
• W2094129893 countsByYear W20941298932012 @default.
• W2094129893 countsByYear W20941298932013 @default.
• W2094129893 countsByYear W20941298932014 @default.
• W2094129893 countsByYear W20941298932015 @default.
• W2094129893 countsByYear W20941298932017 @default.
• W2094129893 countsByYear W20941298932018 @default.
• W2094129893 countsByYear W20941298932019 @default.
• W2094129893 countsByYear W20941298932020 @default.
• W2094129893 countsByYear W20941298932021 @default.
• W2094129893 countsByYear W20941298932022 @default.
• W2094129893 countsByYear W20941298932023 @default.
• W2094129893 crossrefType "journal-article" @default.
• W2094129893 hasAuthorship W2094129893A5012365523 @default.
• W2094129893 hasAuthorship W2094129893A5015471784 @default.
• W2094129893 hasAuthorship W2094129893A5018662602 @default.
• W2094129893 hasAuthorship W2094129893A5019279914 @default.
• W2094129893 hasAuthorship W2094129893A5024768204 @default.
• W2094129893 hasAuthorship W2094129893A5025675098 @default.
• W2094129893 hasAuthorship W2094129893A5045012584 @default.
• W2094129893 hasAuthorship W2094129893A5054774219 @default.
• W2094129893 hasAuthorship W2094129893A5055253820 @default.
• W2094129893 hasAuthorship W2094129893A5062613865 @default.
• W2094129893 hasAuthorship W2094129893A5085708536 @default.
• W2094129893 hasAuthorship W2094129893A5087336965 @default.
• W2094129893 hasAuthorship W2094129893A5090037493 @default.
• W2094129893 hasBestOaLocation W20941298931 @default.
• W2094129893 hasConcept C126322002 @default.
• W2094129893 hasConcept C141071460 @default.
• W2094129893 hasConcept C142724271 @default.
• W2094129893 hasConcept C164705383 @default.
• W2094129893 hasConcept C204787440 @default.
• W2094129893 hasConcept C27081682 @default.
• W2094129893 hasConcept C2777628954 @default.
• W2094129893 hasConcept C2778653478 @default.
• W2094129893 hasConcept C2780868729 @default.
• W2094129893 hasConcept C2908647359 @default.
• W2094129893 hasConcept C54847362 @default.
• W2094129893 hasConcept C71924100 @default.
• W2094129893 hasConcept C90924648 @default.

• next